Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CT-2008-01: CT-011 plus FOLFOX versus FOLFOX in untreated metastatic colorectal adenocarcinoma
2009-014593-18Phase 2Completed
- Sponsor
- CureTech
- Start
- Nov 2009
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2 trial of pembrolizumab in colorectal adenocarcinoma and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by CureTech. Primary endpoint: Median progression-free survival. Started Nov 2009; status: completed.
02
Drugs
03
Conditions
colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on 2009-014593-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-014593-18.